Jeffrey Dayno, MD, is the President and CEO of Harmony Biosciences, a company dedicated to developing innovative treatments for rare neurological diseases. With over 25 years of experience in the pharmaceutical industry and a background as a practicing neurologist, Dr. Dayno has been instrumental in advancing the company's clinical development programs and commercial strategies.
Who is the CEO of Harmony Biosciences?
With a distinguished career spanning over 25 years in the pharmaceutical industry, Jeffrey Dayno, MD, currently serves as the President and CEO of Harmony Biosciences. Before stepping into his current role, Dr. Dayno held pivotal positions at Harmony, including Chief Medical Officer and Executive Vice President. His extensive background includes leadership roles at Merck & Co., Cephalon, and ViroPharma.
Recognized as a national expert in neuroscience, Dr. Dayno has been instrumental in advancing Harmony's clinical development programs and commercial strategies, driving the company's mission to develop innovative treatments for rare neurological diseases.
Work History
Jeffrey Dayno, MD, has an extensive work history in the pharmaceutical industry, holding various leadership positions across several companies. Here is a detailed list of his previous roles:
- Harmony Biosciences - President & Chief Executive Officer (April 2023 - Present)
- Harmony Biosciences - Interim Chief Executive Officer (January 2023 - April 2023)
- Harmony Biosciences - Executive Vice President and Chief Medical Officer (November 2017 - January 2023)
- Egalet Corporation - Chief Medical Officer (July 2014 - November 2017)
- ViroPharma Incorporated - Vice President, Global Medical Affairs (August 2011 - April 2014)
- Labopharm - Chief Medical Officer (May 2010 - July 2011)
- Cephalon - Vice President, Medical Affairs (December 2005 - April 2010)
- Merck - Senior Medical Director (January 1998 - January 2005)
Education History
Jeffrey Dayno, MD, has a robust educational background that laid the foundation for his distinguished career in the pharmaceutical industry. He earned his Doctor of Medicine (MD) from Temple University - Lewis Katz School of Medicine, where he studied from 1985 to 1988. Prior to his medical education, Dr. Dayno completed his undergraduate studies at Trinity College-Hartford, obtaining a Bachelor of Arts (B.A.) in International/Global Studies between 1975 and 1979. This diverse academic journey equipped him with a broad perspective and a solid grounding in both medical and global studies.
When did Jeffrey Dayno, MD join Harmony Biosciences?
Jeffrey Dayno, MD, joined Harmony Biosciences when the company was founded in 2017. Initially serving as the Chief Medical Officer and Executive Vice President, he played a crucial role in the company's early development and strategic direction. On January 1, 2023, Dr. Dayno stepped into the role of Interim Chief Executive Officer, a position he held until April 1, 2023, when he was officially appointed as the President and Chief Executive Officer.
This marks his tenure at Harmony Biosciences as spanning over six years, during which he has been instrumental in advancing the company's mission to develop innovative treatments for rare neurological diseases.